biktarvi yet earn stripe
follow miss result gilead stock price fallen
gilead paid price compani fairli narrow
therapeut focu miss key franchis hepat hcv
hiv led discomfort among investor howev believ
worri overdon heavi eros hcv alreadi
flag compani neither hcv-specif group-level
guidanc chang hiv miss in-line product
inventori relat situat mirror competitor
glaxosmithklin newcom biktarvi post small number expect
product week beyond launch perhap lack
emphat beat scare think outlook gilead
chang materi see trough earn hiv
continu main sourc growth near term unalt
dcf-deriv price target impli upsid current
share price valuat unchalleng core earn
think attract entri point share although
seem like perform stronger
hcv stiff competit previou foray
hcv go well return market last year
mavyret profil much closer gilead offer mavyret
captur market share gilead third major player merck
erod price gilead messag consist
expect stabl second half year made
minor adjust forecast expect global hcv sale
fy declin fall lower end
gilead estim declin expect manag
key wors
hiv inventori movement muddi water de-stock
gener miss genvoya descovi establish drug
biktarvi number met expect enough off-set
disappoint well number import
see biktarvi first full quarter broader
access time around forecast big drug
peak sale
gilead balanc sheet remain strong compani
cash equival end sensibl deploy
would like taken posit
chang made note
price target usd chang
buy chang
perform rel
compani base us
global biopharmaceut
profit loss summari
growth margin
gener sale peak gilead hepat
franchis steep declin creat disappoint
howev franchis long cash-gen tail
major part gilead busi drug treat hiv
remain strong compani success drive uptak
gilead pipelin larg ignor could sourc
upsid posit result forthcom
even kite acquisit share offer good
 option compani strong balanc sheet
valuat dcf-deriv
chang net debt
average cost debt
risk invest thesi
manag fail find deal excit investor enough get
share price move
price volum hepat driven even
competit hiv becom tougher expect competitor
success develop new drug becom challeng product
royalti contract revenu
sale
research develop
 sale
sell gener administr
 revenu
net tax
net incom attribut
net incom attribut
net incom attribut
net incom attribut
weight averag number share dilut million
cash equival
account receiv net allow
prepaid expens current asset
long term proport prepaid royalti
accru govern rebat
current portion long term debt oblig net
commit conting
equiti portion current redeem convert
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
purchas market secur
proce sale market secur
proce matur market secur
acquisit net cash acquir
net cash use invest activ
net cash use invest activ
net cash use invest activ
net cash use invest activ
proce debt financ net issuanc cost
proce convert note hedg
purchas convert note hedg
proce issuanc common stock
repurchas common stock
repay debt oblig
payment settl warrant
payment dividend
contribut non-controlling interest
net cash use financ actviti
net cash use financ actviti
net cash use financ actviti
net cash use financ actviti
effect fx cash cash equival
increas cash cash equival
cash equival begin
cash equival end
cash equival end
cash equival end
cash equival end
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
